drugset / Trial / NCT05164003
CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase1)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the safety and pharmacodynamic of CORETOX® in the treatment of post-stroke upper limb spasticity
Timeline
- Start
- 2017-07-17
- Primary completion
- 2017-09-29
- Completion
- 2017-09-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Botulinum toxin type A | Protein / enzyme biologic | 360 iu | Other |
| Subject | CORETOX® | Unknown | 360 iu | Other |
Indications
No indication recorded.